The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Frontline ibrutinib + venetoclax in CLL: Results from a fixed duration cohort of the CAPTIVATE study
Featured:
Constantine TamDuring the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What are the results from a fixed duration cohort of the CAPTIVATE study?
Frontline ibrutinib + venetoclax in CLL: Results from a fixed duration cohort of the CAPTIVATE study
In this video, Tam discusses results from the phase II CAPTIVATE study (NCT02910583) investigating frontline ibrutinib and venetoclax in a chronic lymphocytic leukemia (CLL) cohort. He reports a complete remission or complete remission with incomplete count recovery rate of 56% and measurable residual disease negativity in 78% of patients.